Newsfeeds - Spark Newswire - Page 3

Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Read More

1 minute read

Supernus Pharmaceuticals Q2 EPS $0.43 Beats $0.20 Estimate, Sales $141.30M Beat $134.87M Estimate

By Benzinga Newsdesk

Today, 10:19 AM

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.20 by 115 percent. This is a 33.85 percent decrease over earnings of $0.65 per share

Read More

24 minute read

Earnings Scheduled For August 4, 2021

By Benzinga Insights

Today, 10:19 AM

Companies Reporting Before The Bell • UroGen Pharma (NASDAQ:URGN) is projected to report earnings for its second quarter.

Read More

2 minute read

News

Supernus Pharmaceuticals Says On Jul. 13 Entered API Supply Agreement With Bachem Americas; Financial Terms Not Disclosed

Today, 10:19 AM

July 13, 2021, Supernus Pharmaceuticals, Inc. (“Supernus” or the “Company”) entered into an API Supply Agreement with Bachem Americas, Inc. (“Bachem”) (the

Read More

8 minute read

Stocks That Hit 52-Week Highs On Wednesday

By Benzinga Insights

Today, 10:19 AM

Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs.

Read More

26 minute read

Uncategorized

Earnings Scheduled For May 5, 2021

By Benzinga Insights

Today, 10:19 AM

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.

Read More

8 minute read

Uncategorized

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge

By Shanthi Rexaline

Today, 10:19 AM

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.

Read More

5 minute read

Uncategorized

Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates

By Shanthi Rexaline

Today, 10:19 AM

Following a mixed month in April, the Food and Drug Administration sets out to review another slate of drugs in May.